CSIMarket Company Name, Ticker, Customers, else..
 

Intercept Pharmaceuticals inc   (NASDAQ: ICPT)

Intercept Pharmaceuticals Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

ICPT Sales vs. its Competitors Q3 2023


Comparing the current results to its competitors, Intercept Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2023 by 14.44 % year on year.
The sales growth was above Intercept Pharmaceuticals Inc 's competitors' average revenue growth of 0.93 %, achieved in the same quarter.

• List of ICPT Competitors





Revenue Growth Comparisons




Net Income Comparison

Intercept Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 90.42 %

<<  ICPT Stock Performance Comparisons





  

Overall company Market Share Q3 2023
Intercept Pharmaceuticals inc achieved revenue growth of 14.44 % in Overall company, and improved market share, to approximately 0.09 %.


<<  More on ICPT Market Share.
 
*Market share is calculated based on total revenue.

  News about Intercept Pharmaceuticals inc Contracts

Recent Advances in the Treatment and Understanding of Primary Biliary Cholangitis: A Comprehensive Overview of Key Findings from Digestive Disease Week 2024 Conference

May 9, 2024
 Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects middle-aged women. With limited treatment options available, the need for innovative therapies is pressing. In this article, we present a comprehensive overview of the recent advancements in the understanding and treatment of PBC, as showcased in the outstanding research and data presented at the Digestive Disease Week (DDW) 2024 conference.Intercept Pharmaceuticals Unveils Exciting New Data:Intercept Pharmaceuticals, a biopharmaceutical company dedicated to developing therapeutics for rare liver diseases, unveiled five compelling abstracts related to PBC at the DDW 2024 conference. These abstracts highlight signif...





Publicly Traded Peers of Intercept Pharmaceuticals inc




Iveric Bio Inc
Share Performance



+252.92%
One Year
Iveric Bio Inc
Profile

Iveric Bio Inc's business model involves the development and commercialization of innovative gene therapy treatments for the treatment of retinal diseases.

More about Iveric Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5,476.626 mill. $ - mill. $ -222.904 mill.


Adagene Inc
Share Performance



-15.09%
30 Days
Adagene Inc
Profile

Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.

More about Adagene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 205.931 mill. $ 7.671 mill. $ -17.609 mill.


Adc Therapeutics Sa
Share Performance



-63.07%
This Year
Adc Therapeutics Sa
Profile

Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.

More about Adc Therapeutics Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 201.521 mill. $ 79.584 mill. $ -96.908 mill.


Nuvalent Inc
Share Performance



+0.05%
Over The Past 5 Days
Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.


Rhythm Pharmaceuticals Inc
Share Performance



-4.08%
Over The Past 5 Days
Rhythm Pharmaceuticals Inc
Profile

Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.

More about Rhythm Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,982.733 mill. $ 239.918 mill. $ -210.222 mill.

177 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Intercept Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intercept Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.